Shosuke Kita

Chuo, 1040045, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer.

Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer.

Journal: Breast cancer research and treatment

Published: January 23, 2026

Cancer genome profiling in sarcomas: current status and future perspectives in Japan.

Cancer genome profiling in sarcomas: current status and future perspectives in Japan.

Journal: Expert review of anticancer therapy

Published: January 16, 2026

Baseline risk variability by eligibility criteria in Cohort 1 of the monarchE trial for high-risk HR-positive, HER2-negative breast cancer.

Baseline risk variability by eligibility criteria in Cohort 1 of the monarchE trial for high-risk HR-positive, HER2-negative breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: April 19, 2025

Treatment and Reasons for Choosing Treatment in Breast Cancer Patients Who Underwent Next-Generation Sequencing Test.

Treatment and Reasons for Choosing Treatment in Breast Cancer Patients Who Underwent Next-Generation Sequencing Test.

Journal: Oncology

Published: October 24, 2024

Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).

Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).

Journal: Breast cancer (Tokyo, Japan)

Published: September 20, 2024

Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum-Based Therapy.

Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum-Based Therapy.

Journal: Head & neck

Published: September 13, 2024

Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).

Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).

Journal: Breast cancer (Tokyo, Japan)

Published: April 26, 2024

Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.

Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.

Journal: Breast cancer (Tokyo, Japan)

Published: March 18, 2024

Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis.

Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis.

Journal: Anticancer research

Published: March 01, 2024

Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.

Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.

Journal: Virchows Archiv : an international journal of pathology

Published: May 19, 2023

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM).

Journal: NPJ breast cancer

Published: March 10, 2023

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer.

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer.

Journal: Frontiers in oncology

Published: February 03, 2023

Showing 1-12 of 16

Last Updated: 09/26/2026